Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.

Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.

Item
http://www.wikidata.org/entity/Q36991121
Barriers to a cure for HIV in womenIs It Important to Consider Sex and Gender in Neurocognitive Studies?How to study the impact of sex and gender in medical research: a review of resourcesThe Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Women's involvement in clinical trials: historical perspective and future implicationsIssues in women's participation in a phase III community HIV vaccine trial in ThailandBreaking the Cycle: Estrous Variation Does Not Require Increased Sample Size in the Study of Female RatsA review of drug-drug interactions in older HIV-infected patients.Reporting of sex and gender in randomized controlled trials in Canada: a cross-sectional methods study.Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
P2860

Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.

Item
http://www.wikidata.org/entity/Q36991121
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Participation of women and sex ...... roved by the FDA in 2007-2009.
@en
type
label
Participation of women and sex ...... roved by the FDA in 2007-2009.
@en
prefLabel
Participation of women and sex ...... roved by the FDA in 2007-2009.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Participation of women and sex ...... proved by the FDA in 2007-2009
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932